

## **Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors**

CAMBRIDGE, Mass., Feb. 6 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced the election of Dr. Derek M. Winstanly to the Company's Board of Directors. His appointment increases Xanthus' board to six members, including five non-employee directors.

Dr. Winstanly currently serves as Executive Vice President, Strategic Business Partnerships for Quintiles Transnational Corp., a global leader in the Contract Research Organization (CRO) industry and also serves on the Quintiles Japan Management Board. In his Executive Vice President role, Dr. Winstanly works with senior executives of pharmaceutical and biotechnology companies to develop long-term strategic business relationships and new business models that complement Quintiles' core businesses. Dr. Winstanly joined Quintiles in 1999 as President of Quintiles Japan. Prior to Quintiles, he spent 15 years with Glaxo Wellcome, plc, now GlaxoSmithKline, in various senior management roles including President of Nippon Wellcome KK (Japan), Chairman & CEO of Glaxo South Africa, and Director of Strategy & New Business Development. Dr. Winstanly serves as a Trustee of the Medical University of South Africa, Medunsa.

"Derek's skills and experience will complement those of the existing board members and management team and enhance Xanthus' ability to develop strategic initiatives as we broaden and deepen our clinical pipeline," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "Derek's in-depth knowledge of clinical development, regulatory, and medical affairs in the global pharmaceutical industry will provide great assistance to our team as our clinical compounds rapidly progress through development."

Dr. Winstanly graduated with a MBChB from the University of Pretoria, South Africa in 1972 and is registered as a Medical Practitioner in both the U.K. and South Africa.

About Xanthus Life Sciences, Inc.

Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at <http://www.xanthus.com>.

Contacts:

Kari Watson, MacDougall Biomedical Communications, Inc. --  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com) or (508) 647-0209

John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences, Inc. --  
john.mccarthy@xanthus.com or (617) 225-0522, x 125

SOURCE Xanthus Life Sciences, Inc.

-0- 02/06/2006

/CONTACT: Kari Watson, MacDougall Biomedical Communications, Inc.,  
+1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr., Senior Vice  
President & CFO, of Xanthus Life Sciences, Inc., +1-617-225-0522, ext. 125,  
john.mccarthy@xanthus.com/

/First Call Analyst: /

/FCMN Contact: /

/Web site: <http://www.xanthus.com/>